366 related articles for article (PubMed ID: 29961562)
21. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
Nand N; Giri K; Jain D
J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
[TBL] [Abstract][Full Text] [Related]
22. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
23. Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease.
Pergola PE; Belo D; Crawford P; Moustafa M; Luo W; Goldfarb-Rumyantzev A; Farag YMK
Am J Nephrol; 2021; 52(7):572-581. PubMed ID: 34293738
[TBL] [Abstract][Full Text] [Related]
24. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
[TBL] [Abstract][Full Text] [Related]
25. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
26. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
[TBL] [Abstract][Full Text] [Related]
27. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Khoury A; Pagan KA; Farland MZ
Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
[TBL] [Abstract][Full Text] [Related]
28. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
29. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
31. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
[TBL] [Abstract][Full Text] [Related]
32. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
[TBL] [Abstract][Full Text] [Related]
33. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
Usmanov RI; Zueva EB; Silverberg DS; Shaked M
J Nephrol; 2008; 21(2):236-42. PubMed ID: 18446719
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
Röhrig G; Steinmetz T; Stein J; Geisel T; Virgin G; Schaefer R; Bach M; Schulz RJ
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():48-53. PubMed ID: 25351027
[TBL] [Abstract][Full Text] [Related]
35. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
36. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
37. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.
Beck-da-Silva L; Piardi D; Soder S; Rohde LE; Pereira-Barretto AC; de Albuquerque D; Bocchi E; Vilas-Boas F; Moura LZ; Montera MW; Rassi S; Clausell N
Int J Cardiol; 2013 Oct; 168(4):3439-42. PubMed ID: 23680589
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
39. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
[TBL] [Abstract][Full Text] [Related]
40. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
